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Toulouse, France; and Melbourne, Victoria, AustraliaObjectives This study sought to measure muscle sympathetic nerve activity (MSNA) in patients with
aortic stenosis (AS) before and after transcatheter aortic valve implantation (TAVI) and to compare
MSNA with that of control patients.
Background TAVI is an emerging therapeutic option in patients with severe AS at high risk of open
heart surgery. Whether patients with AS have increased sympathetic activity remains to be established,
and the effects of TAVI on the sympathetic nervous system are also unknown.
Methods We prospectively enrolled 14 patients with severe symptomatic AS treated by TAVI.
Fourteen control patients matched for age, body mass index, and unscathed of AS were also included.
All patients underwent MSNA and arterial baroreﬂex gain assessment at baseline and 1 week after TAVI
for AS patients.
Results Patients with AS had lower blood pressure (BP) levels, a signiﬁcant increase in MSNA
(61.0  1.7 burst/min vs. 55.4  1.4 burst/min; p < 0.05), and a decrease in arterial baroreﬂex gain
(2.13  0.14% burst/mm Hg vs. 3.32  0.19% burst/mm Hg; p < 0.01) compared with matched control
patients. The TAVI procedures induced an increase in BP associated with a signiﬁcant decrease in
MSNA (from 61.0  1.7 burst/min to 54.1  1.0 burst/min; p < 0.01) and was associated with
a signiﬁcant increase in arterial baroreﬂex gain (from 2.13  0.14% burst/mm Hg to 3.49  0.33%
burst/mm Hg; p < 0.01).
Conclusions We report for the ﬁrst time, through direct measurement of nerve activity, that patients
with AS have increased sympathetic nervous system activity associated with a decrease in sympathetic
baroreﬂex gain and that TAVI normalizes these parameters. This study provides evidence of a new
beneﬁcial effect of TAVI, namely, normalization of sympathetic nervous system hyperactivity.
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1196In developed countries, aortic stenosis (AS) is the most
prevalent of all valvular heart diseases (1,2). Symptomatic
patients have a dire outlook, with three-fourths dying within
3 years of symptom onset. Surgical aortic valve replacement
is currently the gold standard treatment for patients with
severe symptomatic AS (3,4). However, 33% of all patients
75 years and older with severe AS are not surgical candidates
(5). In this context, transcatheter aortic valve implantation
(TAVI) is an emerging therapeutic option in patients
with AS at high risk of open heart surgery (6–9).Whether
patients with AS have increased sympathetic activity re-
mains to be established. As AS worsens, cardiac output is
reduced, and this situation may increase sympathetic nervous
system (SNS) activity as in patients with chronic heart
failure (CHF). An increase in SNS activity may trigger or
exacerbate many of the pathophysiological features associ-
ated with AS such as cardiac hypertrophy and decreased
peripheral perfusion (mediated by both low cardiac outputAbbreviations
and Acronyms
AS = aortic stenosis
CHF = chronic heart failure
DBP = diastolic blood
pressure
MAP = mean arterial
blood pressure
MSNA = muscle sympathetic
nerve activity
SNS = sympathetic nervous
system
TAVI = transcatheter aortic
valve implantation
TF = transfemoraland systemic vasoconstriction).
Moreover, sympathetic outﬂow
stimulates renin release from the
kidney and potentiates the
described mechanisms (ﬂuid and
sodium retention promoting
pulmonary congestion but also
systemic vasoconstriction or
cardiac failure). Finally, sympa-
thetic stimulation increases heart
rate, which shortens the diastolic
ﬁlling period andmay increase the
risk of cardiac ischemia. Thus,
increased SNS activity may
represent an important risk factor
for the progression and prognosis
of AS patients. Sympathetic acti-vation has been identiﬁed in patients with multiple cardio-
vascular conditions (i.e., arterial hypertension, CHF). Inmost
cases, SNS activation is a marker of a poor prognosis, and
therapeutic interventions leading to a decrease in SNS activity
are usually associated with a beneﬁcial outcome (i.e., beta-
blockers in heart failure, hypertension, or ischemic heart
disease). Until now, it has remained unknown whether
sympathetic tone is increased in patients with AS, and, if so,
which mechanisms are involved. Moreover, the effect of
AS treatment on autonomic tone has never been studied
adequately because sympathetic nerve activity and related
reﬂexes have not been directly measured in this pathological
condition. This question is clinically relevant because identi-
ﬁcation of increased sympathetic tone in AS patients could
explain the progression and prognosis of this condition.
Finally, it could be assumed that AS treatment that alleviates
the obstruction of blood ﬂow and eliminates afterload
mismatch may normalize sympathetic activity and improve
the prognosis of patients (9,10).The present study was undertaken to determine whether
AS is associated with an increase in sympathetic nerve ac-
tivity as assessed directly by muscle sympathetic nerve
activity (MSNA) recording. Thus, we aimed to investigate
the role of sympathetic baroreﬂex function in the genesis of
this elevated sympathetic tone. Finally, we also assessed
MSNA and calculated sympathetic baroreﬂex function in
AS patients before and after TAVI as well as in a control
group of patients (without AS) matched for age and body
mass index.
Methods
Patients. Between January and April 2011, we prospectively
enrolled in this study high-risk patients with severe symp-
tomatic AS (aortic valve area <1 cm2 or 0.6 cm2/m2 of body
surface area) treated by TAVI at the Rangueil University
Hospital, Toulouse, France. Patients were considered at high
risk of surgery on the basis of clinical judgment after multi-
disciplinary evaluation including cardiologists (interventional
and noninterventional), cardiovascular surgeons, cardiovas-
cular anesthesiologists, and geriatricians and on a quantitative
assessment of the expected operative mortality by the Logistic
European System for Cardiac Operative Risk Evaluation
(EuroSCORE) (11) and on the Society of Thoracic Surgeons
score (12). Patients treated by TAVI were selected following
the recommendations of the position statement from the
European Association for Cardio-Thoracic Surgery/Euro-
pean Society of Cardiology/European Association of
Percutaneous Cardiovascular Interventions (4) and had
a logistic EuroSCORE >20% or a Society of Thoracic
Surgeons score >10%, or other risk factors not covered by
scores such as chest radiation, porcelain aorta, and liver
cirrhosis. Extreme frailty precluding any invasive intervention,
comorbidities limiting life expectancy to <1 year, coagulop-
athy, sepsis including active endocarditis, active digestive
bleeding, and recent (<30 days) ST-segment elevation
myocardial infarction were considered exclusion criteria for
this study. At admission, all patients underwent coronarog-
raphy and transthoracic echocardiography with measurement
of all conventional parameters.
Control patients matched for age, body mass index, and
without AS were also included.
The research protocol complies with the Declaration
of Helsinki and was approved by the Toulouse University
Hospital Human Research and Ethics Committee. In-
formed written consent was obtained from all participants.
Transfemoral TAVI. The retrograde transfemoral (TF)
approach was used as the ﬁrst option whenever possible.
Both devices currently available during the study were
implanted: the Edwards XT valve delivered by its NovaFlex
catheter requiring a 16- or 18-F sheath (Edwards Life-
sciences Inc., Irvine, California) and the third-generation
Medtronic CoreValve ReValving System requiring an 18-F
Figure 1. Microneurography Recording
The different steps of microneurography recording are shown. The objective is
to record the electrical depolarization of sympathetic nervous system ﬁber
contained in ﬁbular nerves. (A) Demonstration of recording electrode inserted
in themuscle fascicle of the peroneal nerve plus a reference electrode inserted 2
or 3 cm away. (B) Microneurography as a recording of sympathetic muscular
and vascular efference. (C) Microneurographic needle electrode (on the left)
compared with a 30-gauge needle. (D) Example of a microneurographic
recording of sympathetic nervous system activity as a sequence of bursts.
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1197sheath (Medtronic, Minneapolis, Minnesota). Procedures
were performed in a catheterization laboratory, with patients
under general anesthesia, with ﬂuoroscopic and trans-
esophageal echocardiography guidance. Details of patient
selection for TAVI, choice of the device, access site
selection, choice of surgical cutdown or percutaneous
approach with pre-closing of the femoral artery were previ-
ously published (8), as well as technical aspects of the
implantations (4,13–16).
Alternative approaches. The transapical approach was
proposed when the TF approach was contraindicated with
the Edwards prosthesis, most of the time because of un-
suitable femoroiliac arterial anatomy for retrograde access.
Procedures were performed in a catheterization labora-
tory, following technical standards previously detailed
(4,17,18), using the ES valve and Ascendra system (Ed-
wards Lifesciences Inc.). When the TF approach was
contraindicated with the Medtronic CoreValve device and
the left subclavian arterial anatomy was deemed suitable
after appropriate screening, a left subclavian Medtronic
CoreValve implantation was performed as previously
described (19).
MSNA assessment. All patients underwent MSNA re-
cording before and a week after TAVI. MSNA assessment
was performed with patients in the supine position under
carefully standardized conditions. MSNA allows a direct
and dynamic evaluation of post-ganglionic SNS activity. As
previously described (20), MSNA was recorded by a tung-
sten microelectrode (shaft diameter, 200 mm) inserted
selectively in sympathetic efferent ﬁbers around the peroneal
nerve. A subcutaneous reference electrode is inserted 2 to
3 cm away from the recording microelectrode (Fig. 1). Once
positioned, the recording microelectrode allows the collec-
tion of the electrical activity of sympathetic contingent,
which appears as a sequence of electrical bursts. In the ab-
sence of sensory stimuli and muscle movement, the potential
difference measured between the 2 microelectrodes is the
sum of the electrical activity of orthosympathetic ﬁbers of
the peripheral muscle vessels. The neural signal is ampliﬁed,
ﬁltered, rectiﬁed, and integrated to obtain a neurogram
identifying trains of SNS discharge visualized as a sequence
of bursts (Fig. 1D). SNS activity can then be expressed as
bursts per min. Heart rate was measured continuously
by electrocardiography (AD Instruments, Castle Hill, New
South Wales, Australia). Blood pressure (BP) was measured
continuously using the Finometer system (Finapress Me-
dical System BV, Amsterdam, the Netherlands). Oxygen
saturation was monitored with a pulse oximeter (AD In-
struments), and respiratory rate was assessed continuously
with a thoracic belt (Pneumotrace II, UFI, Morro Bay,
California).
Arterial baroreﬂex gain determination. The spontaneous
arterial baroreﬂex gain was calculated during the MSNA
exploration. Assessment of spontaneous arterial baroreﬂex
Table 1. Patient Baseline Clinical Characteristics
Measurements
Control Patients
(n ¼ 14)
Patients
(n ¼ 14)
Male 10 (71) 8 (57.1)
Age, yrs 80.0  3.8 84.3  2.1
Body mass index, kg/m2 24.2  1.9 25.3  1.6
NYHA functional class
II 11 (78.6) 2 (14.3)*
III 0 (0) 4 (28.6)y
IV 0 (0) 8 (57.1)y
Symptoms
Angina 0 (0) 5 (35.7)y
Syncope 0 (0) 1 (7.1)
Left ventricular ejection fraction, % 59.7  1.2 50.4  4.7
Hemoglobin, g/dl 12.1  0.8 11.8  0.6
Creatinine clearance, ml/min 68.5  6.3 62.2  5.8
Treatments at exploration time
Beta-blockers 2 (14.3) 4 (28.6)
ACEi þ AT1 receptor blocker 6 (42.8) 3 (21.4)
Values are n (%) or mean  SEM. *p < 0.01 versus control patients. yp < 0.05 versus control
patients.
ACEi ¼ angiotensin-converting enzyme inhibitor; NYHA ¼ New York Heart Association.
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1198gain was performed as described previously (21). Brieﬂy,
over a 3- to 5-min resting period, diastolic blood pressure
(DBP) values of individual heart beats were grouped in
intervals of 2 mm Hg, and for each interval, the percentage
of diastoles associated with a sympathetic burst was plotted
against the mean of the pressure interval (threshold dia-
gram). Muscle sympathetic bursts were advanced by 1.3 s to
compensate for the baroreﬂex delay. The baroreﬂex gain
was deﬁned as the absolute value of the slope of the
regression line.
Follow-up. In-hospital clinical, biological, and transthoracic
echocardiography follow-up were performed before discharge.
Thirty-day follow-up was active, and information was ob-
tained for all survivors by medical visit or direct contact with
their cardiologist. All events and values were prospectively site
recorded. Because of the publication of the Valve Academic
Research Consortium consensus report during analysis of this
study, we decided to retrospectively readjudicate events
according to these harmonized endpoint deﬁnitions (22).
Statistical analysis. The amplitude of each burst was deter-
mined and sympathetic activity was calculated as bursts per
min. MSNA-related data were collected by F.D., A.V., and
M.L., sampled by a research assistant, and analyzed blindly by
investigators. Measurements of MSNA and spontaneous
arterial baroreﬂex and hemodynamic parameters of the 2
periods (before and after TAVI) were compared using a Wil-
coxon test (matched, nonparametric). Parameters determined
for TAVI patients were compared with those for control
patients with a Wilcoxon test (matched, nonparametric).
Testing was 2-sided, and results are presented as the mean 
SEM. Statistically signiﬁcant differences are reported for p
values <0.05. Statistical analyses were performed with
GraphpadPrism5.0 (GraphpadSoftware, La Jolla,California).Results
Clinical characteristics. We enrolled 14 consecutive high-
risk patients with a diagnosis of AS treated by TAVI.Table 2. Effect of TAVI on Hemodynamic Parameters, Sym
Measurements
Control Patients
(N ¼ 14)
Blood pressure, mm Hg
Systolic 124.0  5.0
Diastolic 63.6  3.3
Mean 83.7  2.5
Heart rate, beats/min 77.1  4.8
Oxygen saturation, % 93.8  0.5
MSNA, bursts/min 55.4  1.4
Arterial baroreﬂex gain, %burst/mm Hg 3.32  0.19
Values are mean  SEM. *p < 0.05 versus control patients. yp < 0.05 ver
xp < 0.01 versus control patients.
MSNA ¼ muscle sympathetic nerve activity; TAVI ¼ transcatheter aorticDuring the same period, 14 control patients matched for
age, body mass index, and without AS were prospectively
included. The demographic characteristics of the 2 pop-
ulations did not signiﬁcantly differ (Table 1) except for
AS-related symptoms, with angina and dyspnea being more
prevalent and severe in AS patients.
Assessment of hemodynamic parameters, sympathetic nerve
activity, and sympathetic baroreﬂex function. Baseline
characteristics of AS and control patients are presented in
Table 1. Patient characteristics before and after TAVI are
presented in Table 2. DBP and mean arterial blood pressure
(MAP) were lower in patients with AS before TAVI.
Baseline MSNA was increased in AS patients compared
with control patients (61.0  1.7 burst/min vs. 55.4  1.4
burst/min, p < 0.05). The spontaneous sympathetic arterial
baroreﬂex gain was signiﬁcantly decreased in AS patientspathetic Activity, and Arterial Baroreﬂex
Before TAVI Procedure
(N ¼ 14)
After TAVI Procedure
(N ¼ 14)
111.7  4.7* 125.3  5.1
53.2  2.5* 64.3  3.5y
74.0  2.8* 84.5  3.2y
71.3  3.0 76.7  4.4
93.9  0.6 93.6  0.7
61.0  1.7* 54.1  1.0z
2.13  0.14x 3.49  0.33z
sus before TAVI procedure. zp < 0.01 versus before TAVI procedure.
valve implantation.
Table 3. Effect of TAVI on Hemodynamic Parameters Assessed by
Echocardiography
Measurements
Before TAVI
Procedure
(N ¼ 14)
After TAVI
Procedure
(N ¼ 14)
Aortic valve area, cm2 0.66  0.04 1.55  0.11*
Indexed aortic valve area, cm2/m2 0.39  0.03 0.90  0.07*
Maximum volume, m/s 4.65  0.20 2.45  0.08y
Mean gradient, mm Hg 56.0  4.5 12.85  0.79y
Velocity time integral left ventricular
outﬂow tract, cm/s
19.5  1.6 19.8  1.6
Left ventricular end-diastolic volume, ml 94.2  10.5 90.6  8.4
Left ventricular end-systolic volume, ml 45.3  10.6 37.6  7.6*
Left ventricular ejection fraction, % 50.4  4.7 61.3  4.6
Cardiac output, l/min 3.13  0.24 4.22  0.42*
Values are mean  SEM. *p < 0.05 versus before TAVI procedure. yp < 0.01 versus before TAVI
procedure.
TAVI ¼ transcatheter aortic valve implantation.
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1199before TAVI compared with controls (2.13  0.14 vs. 3.32
 0.19; p < 0.01) (Fig. 2, Table 2).
Effect of TAVI. In patients with AS, TAVI had an expected
effect on hemodynamic parameters with an increase in DBP
and MAP (Table 2). At the cardiac level, aortic valve area
and cardiac output improved, whereas the mean gradient
decreased (Table 3). Despite a trend toward a decrease,
levels of brain natriuretic peptide levels were not signiﬁcantly
different after TAVI (550  153 pg/ml vs. 496  121
pg/ml; NS). TAVI decreased MSNA signiﬁcantly from
61.0  1.7 bursts/min to 54.1  1.0 bursts/min (p < 0.01)
(Table 2). Moreover, TAVI increased the sympathetic
arterial baroreﬂex gain from 2.13  0.14 to 3.49  0.33
(p < 0.01) (Fig. 2, Table 2). No differences were found
between patients treated with an Edwards or CoreValve
prosthesis. In AS patients after TAVI, BP, MSNA, and
sympathetic arterial baroreﬂex gain were not different
compared with control patients, suggesting that TAVI
normalizes SNS activity. There were no signiﬁcant changes
in beta-blocker and/or angiotensin-converting enzyme
inhibitor/AT1 blocker therapy in the AS group after TAVI.Figure 2. Individual Arterial Baroreﬂex Gain (%Bursts/mm Hg) in
Patients Before and After TAVI and in Control Patients
The arterial baroreﬂex gain evaluates the modiﬁcation of sympathetic nervous
system activity consecutively to spontaneous diastolic arterial blood pressure
variation. Transcatheter aortic valve implantation (TAVI) restores arterial
baroreﬂex gain.Procedural characteristics and 30-day follow-up are shown
in Table 4.
Discussion
The novel and important ﬁnding of this study is that SNS
activity is increased and arterial baroreﬂex is impaired in AS
patients. We also showed that TAVI normalizes SNS
activity and restores arterial baroreﬂex gain. We can
hypothesize that decreased arterial baroreﬂex gain contrib-
utes to increased MSNA in AS patients and that TAVI
normalizes SNS activity through enhancement of arterial
baroreﬂex gain. Hence, the progression and prognosis in AS
patients could be related to both hemodynamic impairment
and also sympathoexcitation and additional impairment ofTable 4. Procedural Characteristics and 30-Day Outcome (N ¼ 14)
Approach
Transfemoral 11 (79)
Transapical 2 (14)
Left subclavian 1 (7)
Prosthesis
Edwards Sapien 10 (71)
Medtronic CoreValve 4 (29)
Device success 13 (93)*
Mortality
Intraprocedural 0
30-day all cause 0
30-day cardiovascular 0
Combined safety endpoint (at 30 days)y 1 (7)z
Values are n (%). *1 patient with post-implantation moderate paravalvular regurgitation at
discharge. yCombined safety endpoint: composite of all-cause mortality, major stroke, major
vascular complication, life-threatening bleeding, acute kidney injury stage III, periprocedural
myocardial infarction, repeat procedure for valve-related dysfunction. z1 major vascular
complication.
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1200baroreﬂex restraint of sympathetic tone. This autonomic
dysfunction provides a further possible explanation for the
high incidence of sudden death, mortality, or morbidity
observed in AS patients but also insight into additional
beneﬁts of TAVI.
Determinant of SNS hyperactivity during AS. In this study we
examined the effect of TAVI on SNS activity in AS
patients. There are 3 key observations. First, MSNA was
higher in AS patients than in control patients; this provides
evidence of the ﬁrst time that central sympathetic outﬂow to
the skeletal muscle is increased in AS patients. Second,
MSNA decreased to control patient level after successful
treatment with TAVI. Finally, sympathetic baroreﬂex
function was signiﬁcantly impaired in AS patients but
normalized with treatment of AS by TAVI.
Sympathetic activity may be increased in AS patients in
association with decreased cardiac index and increased left
ventricular volume or left ventricular hypertrophy. These
modiﬁcations seen in patients with hypertrophic cardiomy-
opathy or CHF have been related to sympathetic activation
in association with various hemodynamic and mechanical
modiﬁcations (i.e., decrease in cardiac index, increase in left
ventricular mass) (23). On the other hand, in AS patients, an
increase in left ventricular or atrial pressure and even in
pulmonary arterial pressure may inhibit sympathetic activity
through cardiopulmonary mechanisms (i.e., Bezold-Jarich
reﬂex). In this study, MSNA at rest was signiﬁcantly
increased in AS patients.
The strength of our study is the assessment of sympathetic
nerve activity via direct recording by MSNA. Only a small
number of clinical studies with few patients have investigated
autonomic function in AS thus far. Although these studies
underscore a potential role of increased SNS activity, some of
them have drawbacks such as small sample size, inappropriate
control subjects, or even the absence of any control. Some of
these studies have used indirect SNS measurement tech-
niques, such as heart rate variability (24), known to be inﬂu-
enced by other systems (i.e., nitric oxide release, temperature,
thermoregulation) and do not reﬂect cardiac sympathetic
nerve activity (25) and cardiac norepinephrine spillover (26).
Plasma levels of norepinephrine may also be inﬂuenced by
norepinephrine transporter function. Given that as much as
80% of neuronally released norepinephrine in the heart is
taken up by the neuronal norepinephrine transporter, the
heart is more susceptible than other organs to defects in
norepinephrine transporter function (27). Other studies used
myocardial scintigraphy with 123I-metaiodobenzylguanidine,
which is known to be less informative in patients, especially
when they have severe left ventricular dysfunction (28–30).
Overall, none of these studies directly assessed sympathetic
nerve function or sympathetic baroreﬂex. Among tools able to
measure SNS activity, MSNA remains the gold standard
because of its low intervariability and intravariability as well as
excellent reproducibility, as shown in studies performed inpatients with various conditions (e.g., CHF [26,31], meta-
bolic syndrome [32]). Moreover, available evidence indicates
that indirect assessment of SNS activity cannot always be used
to detect differences in sympathetic activity between patients
and control subjects. Accordingly, our study allows us to draw
a conclusion about increased SNS activity in AS patients.
Effects of TAVI on MSNA. Surgical aortic valve replacement
may damage cardiac autonomic nerves, and the surgical
procedure itself may inﬂuence sympathetic nerve activity.
However, TAVI is less invasive than open surgery and
therefore may minimally affect cardiac autonomic nerves.
AfterTAVI, all patients showed a signiﬁcant increase in aortic
valve area and a signiﬁcant decrease in the left ventricular/
aortic pressure gradient, changes that indicate a successful
hemodynamic outcome of TAVI. After a mean duration of
a week, the elevated MSNA decreased signiﬁcantly to the
normal range. This suggests that TAVI appears to normalize
increased levels of SNS activity in the short term.After TAVI,
we observed an increase inMAP andDBP and a trend toward
an increase in systolic BP. In an experimental model of aortic
occlusion, it was shown that sustained increases in MAP
induce increases in aortic depressor nerve activity, which
persists after the return of MAP to control levels (33). These
observations suggest that increased afterload in AS patients
leads to a decrease in BP at the level of the aortic arch with
a reduction of the depressor effect mediated by baroreceptor
stimulation. After TAVI, the acute and sustained increase in
arterial pressure may produce pressure-induced changes in
afferent baroreceptor nerve activity and could explain the
reduction of MSNA through a baroreﬂex-mediated mecha-
nism. Hence, cardiac output and BP increase appear to be
a major determinant of sympathetic activity. A reduction in
afferent activity from the baroreceptor is considered a possible
cause of sympathetic activation (34). In our study, AS patients
had decreased spontaneous arterial baroreﬂex sensitivity and
increased MSNA compared with control patients. In addi-
tion, after TAVI, arterial baroreﬂex gain increased (from 2.13
 0.14% burst/mm Hg to 3.49  0.33% burst/mm Hg) and
MSNA decreased to control levels (from 61.0  1.7 bursts/
min to 54.1 1.0 bursts/min). Consequently, in patients with
AS, decreased baroreﬂex sensitivity appears to be reversible.
Furthermore, baroreceptor dysfunction may contribute to
increased sympathetic activity in AS patients, and the
reduction in SNS activity after TAVI may be related to the
improvement of baroreﬂex gain. Baroreﬂex gain has been
reported to be impaired in patients with AS (35), mitral
stenosis (36), or CHF (37). Pharmacological intervention as
well as cardiac transplantation leading to improvement of
cardiac output reverses impaired arterial baroreﬂex gain; thus,
a decrease in cardiac outputmay decrease afferent activity from
the baroreceptor and increase SNS activity.
The negative impact of moderate to severe aortic regurgi-
tation after TAVI on 1-year survival was recently described
(38). In this study, we found that in theTAVI cohort, the only
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1201patient without sympathetic baroreﬂex improvement was
the one with moderate post-procedural aortic paravalvular
regurgitation. The hemodynamic consequence of such leaks is
particularly a decrease inDBP. In light of our results, we could
assume that this condition would lead to a decrease in the
depressor effect mediated by aortic baroreceptor stimulation.
It may produce pressure-induced changes in afferent barore-
ceptor nerve activity and could explain the increase inMSNA
via a baroreﬂex-mediated mechanism. Knowing the delete-
rious effect of SNA in other cardiovascular diseases such as
hypertension and CHF, it could be the missing link between
these signiﬁcant regurgitations after TAVI and the associated
poorer survival rate (38).However, our study does not allow us
to draw conclusions from this single case observation, and this
pathophysiological concept would need to be further
evaluated.
Study limitations. Our ﬁndings do not indicate whether the
excessive sympathetic activation occurring in AS is limited
to the muscular vascular area only or whether it is general-
ized to the whole cardiovascular system. Evidence is avail-
able that under similar conditions such as CHF, sympathetic
outﬂow is increased not only at the level of skeletal muscle
but also in the coronary and renal circulation (39). More-
over, a signiﬁcant positive correlation exists between spon-
taneous MSNA (expressed as the number of sympathetic
bursts/min1) and both the spillover of norepinephrine from
the heart and the concentration of norepinephrine in coro-
nary sinus venous plasma, as demonstrated by Leimbach
et al. (23) in 1992 in healthy subjects. Furthermore, a
signiﬁcant correlation between plasma norepinephrine levels
and MSNA was demonstrated in heart failure subjects (23).
We have not assessed baroreceptor reﬂex function by using
intravenous infusion of vasopressor and depressor agents. This
technique cannot be used in patients with severeASbecause of
the high risk of hemodynamic failure after sodium nitro-
prusside or phenylephrine infusion. Moreover, this approach
can be affected by long-term treatment. Finally, there are
several limitations to the interpretation of sympathetic
response to vasoactive drugs, among them nitroprusside
inhibition of sympathetic neurotransmission (40) and
unpredictable effects of cardiac loading conditions on low-
pressure mechanoreceptor nerve ﬁring. We have not investi-
gated other reﬂexes such as chemoreﬂexes or muscular reﬂexes
(i.e., metabomechanoreﬂexes). In this study, we cannot
exclude that other mechanisms were involved in the increase
in SNS activity such as renin-angiotensin system activation.
Finally, further studies are needed to conﬁrmwhetherMSNA
decrease and sympathetic baroreﬂex gain increase after TAVI
are maintained in the long-term.
Conclusions
We provide for the ﬁrst time evidence via direct recording
that SNA is increased in AS patients. Levels of SNSactivity decreased to the normal range after TAVI, which
increased cardiac output and sympathetic baroreﬂex func-
tion. These data illustrate the unknown effects of TAVI
on SNA and baroreﬂex gain. Knowing that SNS hyper-
activity and baroreﬂex dysfunction are prognostic of
a poor outcome in various conditions (i.e., CHF, metabolic
syndrome), our results provide insight and explanation
about how TAVI, in addition to its hemodynamic effect,
could reduce morbidity and mortality in AS patients. This
opens the path for new research on autonomic markers as
diagnostic, therapeutic, and prognostic tools for the
management and follow-up of AS patients.
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